Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection

详细信息    查看全文

• 作者：Asuncion Mejias ; MD ; PhD ; MSc^a ; ^{asuncion.mejias@nationwidechildrens.org} ; Cristina Garcia-Maurino ; MD^a ; Rosa Rodriguez-Fernandez ; MD ; PhD^a ; ^b ; Mark E. Peeples ; PhD^a ; Octavio Ramilo ; MD^a ; ^{octavio.ramilo@nationwidechildrens.org}
• 关键词：RSV ; Monoclonal antibodies ; Nanobodies
• 刊名：Vaccine
• 出版年：2017
• 出版时间：11 January 2017
• 年：2017
• 卷：35
• 期：3
• 页码：496-502
• 全文大小：741 K
• 卷排序：35

文摘

Promising antibodies are in development for prevention and treatment of RSV infections. Newer mAb with augmented potency and half-life have been developed for the prevention of RSV. Nanobodies delivered intranasally are an attractive approach for the treatment of acute RSV infections. Evaluation of these newer strategies should include patient follow up to determine their impact on long-term lung morbidity.